ASH 2023 | What’s on the horizon for Hodgkin lymphoma?
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, provides insights into what is on the horizon for the treatment of Hodgkin lymphoma (HL). He mentions promising results of CAR-T therapies, as well as bispecific antibodies combined with natural killer (NK) cells derived from donated umbilical cord blood. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
I think just like other lymphomas, the whole thing about bringing new cellular therapies to bear, I think, is going to really make a big difference to Hodgkin in the future. We’ve tinkered with it a little bit. The initial results have been quite promising. The durability has not been quite as good as other lymphomas, but as that gets refined, I think we’re going to see those results be even better...
I think just like other lymphomas, the whole thing about bringing new cellular therapies to bear, I think, is going to really make a big difference to Hodgkin in the future. We’ve tinkered with it a little bit. The initial results have been quite promising. The durability has not been quite as good as other lymphomas, but as that gets refined, I think we’re going to see those results be even better. That’s with CAR-T’s. But we’re also seeing utilization of bispecific antibodies on NK cells. And there are some really encouraging data also presented previously but updated at the ASH meeting showing that if you take cord-blood NK cells, activate them, add a bispecific that binds to CD30 but also to CD16, you can get a very, very high response rate that, when you redose, can actually be made to be more durable. So I think these are things that are pretty exciting for Hodgkin lymphoma.
Read more...
Disclosures
ADC Therapeutics: Research Funding; Pfizer: Research Funding; AstraZeneca: Research Funding; Affimed: Research Funding; Takeda: Research Funding; SeaGen: Research Funding; BMS: Research Funding; Regeneron Pharmaceuticals, Inc.: Research Funding.
